Xeris Biopharma Holdings (XERS) Stock Forecast: StockMap's 2-Week Call
XERS stock forecast: StockMap's model makes no two-week call on Xeris Biopharma Holdings after the Nov 18 close: its evidence is split, 7 reasons for and 8 against. Too few two-week windows graded to judge yet.
Xeris Biopharma Holdings last closed at $16.99, +1.13% on the session.
Against the IVW growth benchmark the position is +1.11% over the forecast window.
Xeris Biopharma Holdings' market cap is $3.10B as of November 18, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 13 (too close to call).
Where XERS sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 7 bullish and 8 bearish.
Agreement across those insights is 47%.
6 daily calls for XERS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Xeris Biopharma Holdings in the 20th percentile on return on equity, where 100 is best.
Xeris Biopharma Holdings is classified under Health Care / Pharmaceuticals.
StockMap tracks Xeris Biopharma Holdings as the 36th largest of the 152 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 74 Moderate Underperform, 47 Neutral and 31 Strong Underperform.
On that composite Xeris Biopharma Holdings ranks 6th of 152 in the group, against a group median of -0.33.